ClinicalTrials.gg
Not yet recruitingNCT07129031Updated Aug 19, 2025

Optimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock

A Phase 3 interventional study of low-titer O-group whole blood and 1:1:1 component transfusion in Hemorrhage, Hemorrhagic Shock and Upper Gastrointestinal Bleeding (UGIB), sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 10 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Primary conditionShock, HemorrhagicRegistry: HemorrhageReclassifiedWhy we changed it
Registry
Hemorrhage — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Hemorrhagic
Why
  1. The study's listed conditions name Shock, Hemorrhagic, a narrower term within Hemorrhage.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Xijing Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
10 Years to 90 Years
Sex
All
01

Study summary

This single-center, prospective, randomized controlled trial was approved by the institutional ethics committee and overseen by an independent data and safety monitoring board. It enrolled patients with hemorrhagic shock caused by trauma or major gastrointestinal bleeding. Using a random-number-table method, participants were allocated to three groups: (1) Control group: standard massive transfusion protocol (MTP) with transfusing type-specific blood components in a 1:1:1 ratio. (2) Type-specific whole-blood group: following emergency ABO typing and cross-matching, type-specific whole blood was transfused. (3) Low-titer group O whole-blood group: in the emergency phase, 4 units of low-titer group O whole blood (anti-A/B IgM titer \< 1:64) were infused; after definitive ABO typing, patients were switched to type-specific whole blood. Clinical data were automatically extracted from the electronic medical record system. Primary endpoints were efficacy (28-day survival), timeliness (transfusion waiting time and time to achieve target mean arterial pressure), cost-effectiveness (total blood consumption and transfusion-related expenses), and safety (transfusion-associated adverse events including TRALI and hemolytic reactions).Statistical analyses included Kaplan-Meier survival curves and Cox proportional-hazards regression, adjusting for confounders such as age and disease severity scores. The advantages and disadvantages of each transfusion strategy were evaluated, and an optimized strategy for emergency blood transfusion in hemorrhagic shock was developed. This strategy was peer-reviewed and refined, culminating in a standardized, multidisciplinary, emergency-transfusion protocol.

02

Conditions studied

  • Hemorrhage
  • Hemorrhagic Shock
  • Upper Gastrointestinal Bleeding (UGIB)

Browse trials for

Keywords

  • Hemorrhagic shock
  • transfusion
  • low-titer O-group whole blood
  • group of 1:1:1 component
  • group of ABO- and Rh-compatible whole blood
03

In context

Shock, Hemorrhagic Reclassified

79 studies on the registry are indexed under Shock, Hemorrhagic; 15 are open to participants now.

This study's planned enrollment of 180 is above the median of 107 across 42 interventional studies indexed under Shock, Hemorrhagic.

Browse Shock, Hemorrhagic studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.

Compared within Shock, Hemorrhagic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hemorrhage. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
10 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with hemorrhagic shock due to trauma or upper gastrointestinal bleeding who meet emergency transfusion criteria ( \< 7 g/dL or active bleeding).

Age 10-90 years. Time from onset to hospital admission \< 24 hours.

Exclusion criteria

Exclusion Criteria:

  • Severe underlying diseases (end-stage organ failure or active ). Known coagulopathy or history of severe transfusion reactions. Refusal to participate or inability to complete follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    group of 1:1:1 component transfusion

    Following the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)", implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets).

    Drug: 1:1:1 component transfusion

  • Active comparator
    group of ABO- and Rh-compatible whole blood

    Administer type-specific whole-blood transfusion in accordance with the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)".

    Drug: ABO- and Rh-compatible whole blood

  • Experimental
    low-titer O-group whole blood

    During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.

    Drug: low-titer O-group whole blood

Interventions

  • Druglow-titer O-group whole blood

    Arm Description: During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.

  • Drug1:1:1 component transfusion

    Following the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)", implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets).

  • DrugABO- and Rh-compatible whole blood

    Administer type-specific whole-blood transfusion in accordance with the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)".

06

What researchers measure

Primary outcomes

  1. survival rate

    Time frame: 24 hours,30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The following de-identified individual participant data (IPD) will be shared via a public repository (Dryad Digital Repository) no later than 12 months after the primary results publication. Participant-level baseline characteristics Age, sex, body-mass index, Injury Severity Score (ISS), baseline hemoglobin, vital signs on arrival, coagulation parameters (INR, platelet count, fibrinogen), lactate. Intervention allocation and delivery data • Randomization group, actual blood products transfused (type, volume, sequence, total units), time from randomization to first transfusion. Primary and secondary outcomes (28-day follow-up) Vital status at 28 days (alive/dead), date and cause of death if applicable. Time to achieve mean arterial pressure ≥ 65 mmHg, total blood products and crystalloids within 24 h, incidence and date of TRALI, TACO, acute hemolytic reactions, ICU length of stay, hospital length of stay, total transfusion-related costs. Safety events All-grade and grade ≥3 ad

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: January 2026-January 2028

Access criteria: 1. The IPD and supporting information will be accessible to the following parties: Principal Investigator (PI) and Study Team: The PI and designated members of the study team, including co-investigators, biostatisticians, and data managers, will have access to the IPD and supporting information for the purpose of conducting the study, analyzing data, and preparing reports. Independent Data and Safety Monitoring Board (DSMB): The DSMB will have access to the IPD and supporting information to monitor the safety and efficacy of the study interventions and to provide recommendations based on interim analyses. Ethics Committees: These committees may request access to the IPD and supporting information to ensure compliance with ethical standards and to review the study protocol and conduct. Sponsor and Sponsor's Representatives: The sponsor of the study and their designated representatives may have access to the IPD and supporting information for oversight and monitoring of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Jun 2027, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2025
First posted
Aug 19, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07129031
Lead sponsor
Xijing Hospital
Responsible party
yin wen (chief physician, Xijing Hospital) — Principal investigator
First posted
Aug 19, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 19, 2025

Study contacts

lijunjie li
study director · Xijing Hospital
liushanshou liu
principal investigator · Xijing Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion